102 related articles for article (PubMed ID: 27914809)
41. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
Pollack IF; Erff M; Ashkenazi A
Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
[TBL] [Abstract][Full Text] [Related]
42. Differential susceptibility of gastric cancer cells to TRAIL-induced apoptosis.
Song NM; Jun S; Zang DY; Kim SG; Park HR; Kang D
Oncol Rep; 2013 Mar; 29(3):1224-30. PubMed ID: 23233033
[TBL] [Abstract][Full Text] [Related]
43. Artesunate enhances TRAIL-induced apoptosis in human cervical carcinoma cells through inhibition of the NF-κB and PI3K/Akt signaling pathways.
Thanaketpaisarn O; Waiwut P; Sakurai H; Saiki I
Int J Oncol; 2011 Jul; 39(1):279-85. PubMed ID: 21537836
[TBL] [Abstract][Full Text] [Related]
44. Glioma progression is suppressed by Naringenin and APO2L combination therapy via the activation of apoptosis in vitro and in vivo.
Song T; Zhang M; Wu J; Chen F; Wang Y; Ma Y; Dai Z
Invest New Drugs; 2020 Dec; 38(6):1743-1754. PubMed ID: 32767162
[TBL] [Abstract][Full Text] [Related]
45. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention.
Ahmad M; Shi Y
Oncogene; 2000 Jul; 19(30):3363-71. PubMed ID: 10918593
[TBL] [Abstract][Full Text] [Related]
46. A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.
James MA; Seibel WL; Kupert E; Hu XX; Potharla VY; Anderson MW
Anticancer Drugs; 2015 Jun; 26(5):518-30. PubMed ID: 25646742
[TBL] [Abstract][Full Text] [Related]
47. Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-kappaB signalling pathway in thyroid cancer cells.
Morello S; Sorrentino R; Porta A; Forte G; Popolo A; Petrella A; Pinto A
J Cell Physiol; 2009 Nov; 221(2):378-86. PubMed ID: 19562684
[TBL] [Abstract][Full Text] [Related]
48. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.
Opel D; Naumann I; Schneider M; Bertele D; Debatin KM; Fulda S
Clin Cancer Res; 2011 May; 17(10):3233-47. PubMed ID: 21355080
[TBL] [Abstract][Full Text] [Related]
49. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
[TBL] [Abstract][Full Text] [Related]
50. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
51. 5-Fluorouracil enhances the chemosensitivity of gastric cancer to TRAIL via inhibition of the MAPK pathway.
Li H; Lv J; Guo J; Wang S; Liu S; Ma Y; Liang Z; Wang Y; Qi W; Qiu W
Biochem Biophys Res Commun; 2021 Feb; 540():108-115. PubMed ID: 33476960
[TBL] [Abstract][Full Text] [Related]
52. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
53. 2'-Hydroxy-4-methylsulfonylchalcone enhances TRAIL-induced apoptosis in prostate cancer cells.
Ismail B; Fagnere C; Limami Y; Ghezali L; Pouget C; Fidanzi C; Ouk C; Gueye R; Beneytout JL; Duroux JL; Diab-Assaf M; Leger DY; Liagre B
Anticancer Drugs; 2015 Jan; 26(1):74-84. PubMed ID: 25192452
[TBL] [Abstract][Full Text] [Related]
54. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells.
Zhang X; Li W; Olumi AF
Clin Cancer Res; 2007 Dec; 13(23):7181-90. PubMed ID: 18056199
[TBL] [Abstract][Full Text] [Related]
55. TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate.
Vindrieux D; Réveiller M; Florin A; Blanchard C; Ruffion A; Devonec M; Benahmed M; Grataroli R
J Cell Physiol; 2006 Mar; 206(3):709-17. PubMed ID: 16245307
[TBL] [Abstract][Full Text] [Related]
56. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Rosato RR; Almenara JA; Coe S; Grant S
Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
[TBL] [Abstract][Full Text] [Related]
57. Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro.
Shimoyama S; Mochizuki Y; Kusada O; Kaminishi M
Int J Oncol; 2002 Sep; 21(3):643-8. PubMed ID: 12168112
[TBL] [Abstract][Full Text] [Related]
58. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression.
Syed V; Mukherjee K; Godoy-Tundidor S; Ho SM
J Cell Biochem; 2007 Oct; 102(2):442-52. PubMed ID: 17393432
[TBL] [Abstract][Full Text] [Related]
59. Adenovirus-mediated gene transfer of caspase-8 sensitizes human adenocarcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand.
Yasui H; Adachi M; Hamada H; Imai K
Int J Oncol; 2005 Feb; 26(2):537-44. PubMed ID: 15645141
[TBL] [Abstract][Full Text] [Related]
60. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
